In addition, PKM2 expression also was demonstrated to be a predictive biomarker of chemotherapeutic sensitivity, such as platinum (Papadaki et al., 2014) and docetaxel (Yuan et al., 2016), as well as radiosensitivity in lung cancers (Meng et al., 2015). The gene discussed is PKM; the disease is lung cancer.